RepliCel Secures New Patents for Tendon Repair Technology

Replicel Life Sciences was granted patents addressing the use of RCT-01 fibroblast cell technology to treat chronically damaged tendons.

The granted patents were received in:

China (Patent No. ZL201480011232.2)
Europe (Patent No. 2956543)
Russia (Patent No. 2678878)


Additionally, U.S. Patent No. 10272118 will be granted...

document icon

You are out of free articles for this month

Subscribe as a Guest for $0 and unlock a total of 5 articles per month.

You are out of five articles for this month

Subscribe as an Executive Member for access to unlimited articles, THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.


Julie Vetalice is ORTHOWORLD's Editorial Assistant. She has covered the orthopedic industry for over 20 years, having joined the company in 1999.

Contact Us